Disease · MONDO_0005996

trichuriasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. trichuriasis. Diseases, record MONDO_0005996. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005996

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: trichuriasis; Open Targets
Open Targets ID: MONDO_0005996; Open Targets
Other names: Infection by Trichuris trichura, Trichuriasis (disorder), Trichuris trichiura caused disease or disorder, Trichuris trichiura disease or disorder, Trichuris trichiura infectious disease, trichuriasis infection, trichuris trichiura infection, whipworm disease; Open Targets
Disease Ontology: DOID:1252; Disease Ontology
MeSH: D014257; MeSH
NCI Thesaurus: C128399; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 5 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALBENDAZOLE	CHEMBL1483	Small molecule	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets
IVERMECTIN	CHEMBL6067487		Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
MEBENDAZOLE	CHEMBL685	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MOXIDECTIN	CHEMBL2104415	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
EMODEPSIDE	CHEMBL2104404	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OXFENDAZOLE	CHEMBL42442	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials21

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03527732	Efficacy and Safety of IVM/ALB Co-administration	Phase 2/3	1,673	2024-03-20	Trichuriasis	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT03527745	Albendazole Dose Finding and Pharmacokinetics in Children and Adults	Phase 2	700	2021-01-06	Trichuriasis, Hookworm Infections	ALBENDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT04700423	Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration	Phase 2/3	536	2024-12-05	Trichuriasis, Ascariasis, Hookworm Infections, Helminthes; Infestation, Intestinal	ALBENDAZOLE, IVERMECTIN, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT02034162	A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants	Phase 3	295	2016-11-04	Helminth Infections	MEBENDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT06184399	Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC	Phase 2	260	2025-09-22	Trichuriasis, Ascariasis, Hookworm Infections	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT04726969	Efficacy and Safety of MOX/ALB Co-administration	Phase 3	255	2023-02-02	Trichuriasis, Ascariasis, Hookworm Infections	ALBENDAZOLE, IVERMECTIN, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT06188715	Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC	Phase 3	224	2025-09-19	Trichuriasis, Ascariasis, Hookworm Infections	ALBENDAZOLE, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT04041453	Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients	Phase 2	176	2020-07-29	Trichuris Infection, Helminthiasis	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT04177654	Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs		9,457		Soil-transmitted Helminth Infections	ALBENDAZOLE, MEBENDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01050452	Safety and Efficacy of Drug Combinations Against Trichuris Trichiura	Not applicable	750		Parasitic Diseases	ALBENDAZOLE, IVERMECTIN, MEBENDAZOLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 21

See all 21 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Double-blind Mebendazole 500 mg vs Double-blind Placebo: Number of Participants Reporting Treatment Emergent Adverse Event (TEAE) in Double-Blind Treatment Period	9 of 144	8 of 140	284	NCT02034162

Source Trial comparisons

Papers from its trials40

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38321011	RESULT	1	PubMed
38163912	RESULT	1	PubMed
37930980	RESULT	1	PubMed
37202027	RESULT	1	PubMed
33292853	RESULT	1	PubMed
33284834	RESULT	1	PubMed
32953118	RESULT	1	PubMed
32397986	RESULT	1	PubMed
30768602	RESULT	1	PubMed
29702653	RESULT	1	PubMed

1 to 10 of 40

See all 40 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005996

GET https://conductscience.org/api/diseases/v1/MONDO_0005996/trials?page=2

API reference For AI assistants